The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

COPD Guideline Revised 2012: Contracted Version

COPD 진료지침 2012 개정(축약본)

  • Published : 2013.03.01
⟨ Previous Next ⟩

Abstract

COPD imposes significant morbidity and mortality in Korea. The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) revised the practice guideline of COPD in 2012. The revised guideline was developed not only with the agreement of the KATRD members but also with the input from the representatives of Korean Physician's Association and Health Insurance Review & Assessment Service. In the revised guideline, recommendations were developed by systematic reviews based on PICO (population, intervention, comparison, and outcome) and GRADE (The Grading of Recommendations Assessment Development and Evaluation). Patients aged over 40 with smoking history, dyspnea, cough, and phlegm should be suspected to have COPD. To confirm and diagnose COPD, pulmonary function test of spirometry is required. In addition to pulmonary function, dyspnea symptom and exacerbation frequency should be evaluated to classify COPD patients into three groups, A, B, and C. The guideline recommends for patients in group A an inhaled short-acting bronchodilator to control the symptoms; for patients in B, an inhaled long-acting anticholinergics or an inhaled long-acting beta2 agonist; for patients in C, an inhaled long-acting anticholinergics, an inhaled long-acting beta2 agonist, or a combination of inhaled corticosteroid and long-acting beta2 agonist (low level of evidence and strong recommendation).

Keywords

References

  1. Hwang YI, Yoo KH, Sheen SS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the result of forth Korean National Health and Nutrition Examination Survey. Tuberc Respir Dis 2011;71:328-334. https://doi.org/10.4046/trd.2011.71.5.328
  2. COAD Research Center. COPD Practice Guidelines [Internet]. Seoul: COAD Research Center, c2012 [cited sep 30 2012]. Available from: http://www.copd-asthma.co.kr/Kor.
  3. GRADE working group. Grading the quality of evidence and the strength of recommendation [Internet]. International: GRADE working group, 2012 [cited sep 30 2012]. Available from: http://www.gradeworkinggroup.org.
  4. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. https://doi.org/10.1183/09031936.06.00025805
  5. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-743. https://doi.org/10.1016/S0140-6736(09)61303-9
  6. Yoo KH, Kim YS, Sheen SS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-665. https://doi.org/10.1111/j.1440-1843.2011.01951.x
  7. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442. https://doi.org/10.1371/journal.pmed.0030442
  8. Oh IH, Yoon SJ, Kim EJ. The burden of disease in Korea. J Korean Med Assoc 2011;54:646-652. https://doi.org/10.5124/jkma.2011.54.6.646
  9. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health 2005;4:7. https://doi.org/10.1186/1476-069X-4-7
  10. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-688. https://doi.org/10.1183/09031936.03.00040703
  11. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185. https://doi.org/10.1183/09031936.00128008
  12. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2012 Aug 9 [Epub]. http://dx.doi.org/10.1164/ rccm.201204-0596PP.
  13. Lee S, Lee JS, Song JW, et al. Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and dyspnea-12 questionnaire. Tuberc Respir Dis 2010;69:171-176. https://doi.org/10.4046/trd.2010.69.3.171
  14. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-191. https://doi.org/10.7326/0003-4819-155-3-201108020-00008
  15. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138. https://doi.org/10.1056/NEJMoa0909883
  16. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-735. https://doi.org/10.1136/thx.2008.108027
  17. Calverley PMA. Symptomatic bronchodilator treatment. In: Calverley PMA, Pride NB, eds. Chronic Obstructive Pulmonary Disease. London: Chapman & Hall, 1995:419-424.
  18. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303. https://doi.org/10.1136/bmj.320.7245.1297
  19. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272:1497-1505. https://doi.org/10.1001/jama.1994.03520190043033
  20. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823. https://doi.org/10.1016/S0140-6736(98)10019-3
  21. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840. https://doi.org/10.1183/09031936.04.00116004
  22. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130:647-656. https://doi.org/10.1378/chest.130.3.647
  23. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2007; 101:2395-2401. https://doi.org/10.1016/j.rmed.2007.06.008
  24. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987;91:804-807. https://doi.org/10.1378/chest.91.6.804
  25. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. https://doi.org/10.1056/NEJMoa063070
  26. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-821.
  27. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995;89:357-362. https://doi.org/10.1016/0954-6111(95)90008-X
  28. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149. https://doi.org/10.1186/1465-9921-11-149
  29. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182:155-162. https://doi.org/10.1164/rccm.200910-1500OC
  30. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice‐daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-279. https://doi.org/10.1183/09031936.00045810
  31. Lipworth BJ, McDevitt DG, Struthers AD. Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy: protection by conventional doses of spironolactone but not triamterene. Chest 1990;98:811-815. https://doi.org/10.1378/chest.98.4.811
  32. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-464. https://doi.org/10.1016/S0024-3205(98)00588-8
  33. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(2):CD002876.
  34. Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008;3:127-136. https://doi.org/10.2147/COPD.S2389
  35. Rossi A, Gottfried SB, Higgs BD, Zocchi L, Grassino A, Milic-Emili J. Respiratory mechanics in mechanically ventilated patients with respiratory failure. J Appl Physiol 1985; 58:1849-1858. https://doi.org/10.1152/jappl.1985.58.6.1849
  36. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456. https://doi.org/10.1016/S0140-6736(03)12459-2
  37. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. https://doi.org/10.1183/09031936.03.00031402
  38. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on chronic obstructive pulmonary disease. N Engl J Med 1999;340:1948-1953. https://doi.org/10.1056/NEJM199906243402503
  39. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416. https://doi.org/10.1001/jama.2008.717
  40. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229. https://doi.org/10.1001/archinternmed.2008.550
  41. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE Study. Chest 2011;139:505-512. https://doi.org/10.1378/chest.09-2992
  42. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26. https://doi.org/10.1164/rccm.200707-973OC
  43. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010;(5):CD007891.
  44. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555. https://doi.org/10.7326/0003-4819-146-8-200704170-00152
  45. Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012;25:40-47. https://doi.org/10.1016/j.pupt.2011.10.006
  46. Hoshino M, Ohtawa J. Effects of adding salmeterol/ fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology 2011;16:95-101. https://doi.org/10.1111/j.1440-1843.2010.01869.x
  47. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63: 592-598. https://doi.org/10.1136/thx.2007.087213
  48. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-750. https://doi.org/10.1164/rccm.200904-0492OC
  49. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012;106: 382-389. https://doi.org/10.1016/j.rmed.2011.09.004
  50. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153(6 Pt 1):1958-1964. https://doi.org/10.1164/ajrccm.153.6.8665061
  51. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994;150:11-16. https://doi.org/10.1164/ajrccm.150.1.8025735
  52. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992;146:800-802. https://doi.org/10.1164/ajrccm/146.3.800
  53. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-571. https://doi.org/10.1016/S0140-6736(05)67100-0
  54. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694. https://doi.org/10.1016/S0140-6736(09)61255-1
  55. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161. https://doi.org/10.1164/rccm.200610-1563OC
  56. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703. https://doi.org/10.1016/S0140-6736(09)61252-6
  57. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987;81: 287-292. https://doi.org/10.1016/0007-0971(87)90163-X
  58. Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(5):CD002309.
  59. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting ${\beta}2$-agonists for COPD: influence of exacerbation history. Eur Respir J 2011;38:553-560. https://doi.org/10.1183/09031936.00178710
  60. Lee SD, Hui DS, Mahayiddin AA, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011;16:1249-1257. https://doi.org/10.1111/j.1440-1843.2011.02038.x
  61. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17(Suppl 1):S91-93. https://doi.org/10.1016/S0264-410X(99)00114-0
  62. Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands. J Epidemiol Community Health 1998;52:120-125. https://doi.org/10.1136/jech.52.2.120
  63. Korea Centers for Disease Control and Prevention. 2011 Epidemiology and Prevention of Vaccine-Preventable Disease [Internet]. Osong: Korea Centers for Disease Control and Prevention, c2012 [cited sep 30 2012]. Available from: http://nip.cdc.go.kr/nip/index.html.
  64. Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003;(1):CD004105.
  65. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178: 1139-1147. https://doi.org/10.1164/rccm.200801-145OC
  66. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10. https://doi.org/10.1186/1465-9921-11-10
  67. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698. https://doi.org/10.1056/NEJMoa1104623
  68. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010;(2):CD001287.
  69. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008;371:2013-2018. https://doi.org/10.1016/S0140-6736(08)60869-7
  70. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Lancet 2005;365:1552-1560. https://doi.org/10.1016/S0140-6736(05)66456-2
  71. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-1413. https://doi.org/10.1164/rccm.200508-1211ST
  72. Lacasse Y, Brosseau L, Milne S, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(3):CD003793.
  73. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(4):CD003793.
  74. Green RH, Singh SJ, Williams J, Morgan MD. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001;56:143-145. https://doi.org/10.1136/thorax.56.2.143
  75. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B; Long-term Oxygen Treatment Trial Research Group. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest 2010;138:179-187. https://doi.org/10.1378/chest.09-2555
  76. Criner G, Cordova FC, Leyenson V, et al. Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit Care Med 1998;157(5 Pt 1):1578-1585. https://doi.org/10.1164/ajrccm.157.5.9607081
  77. Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997;155:1984-1990. https://doi.org/10.1164/ajrccm.155.6.9196106
  78. Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998;157(3 Pt 1):715-722. https://doi.org/10.1164/ajrccm.157.3.9608004
  79. Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006;82:431-443. https://doi.org/10.1016/j.athoracsur.2006.05.069
  80. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report: 2010. J Heart Lung Transplant 2010;29:1104-1118. https://doi.org/10.1016/j.healun.2010.08.004
  81. Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997;155:789-818. https://doi.org/10.1164/ajrccm.155.3.9117010
  82. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update: a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25: 745-755. https://doi.org/10.1016/j.healun.2006.03.011
  83. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613. https://doi.org/10.1164/ajrccm.161.5.9908022
  84. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931. https://doi.org/10.1136/thx.2005.040527
  85. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121. https://doi.org/10.1164/rccm.200506-859OC
  86. Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:742-747. https://doi.org/10.1016/j.rmed.2004.10.020
  87. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl 2):398S-401. https://doi.org/10.1378/chest.117.5_suppl_2.398S
  88. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-1238. https://doi.org/10.1183/09031936.00109906
  89. Mahon JL, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115:38-48. https://doi.org/10.1378/chest.115.1.38
  90. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-2625. https://doi.org/10.1056/NEJMoa023161
  91. De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007;132:1741-1747. https://doi.org/10.1378/chest.07-0208
  92. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358:2020-2025. https://doi.org/10.1016/S0140-6736(01)07097-0
  93. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010;341:c5462. https://doi.org/10.1136/bmj.c5462
  94. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation: a consensus conference report. Chest 1999;116:521-534. https://doi.org/10.1378/chest.116.2.521
  95. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341: 1555-1557. https://doi.org/10.1016/0140-6736(93)90696-E
  96. Organized jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Societe de Reanimation de Langue Francaise, and approved by ATS Board of Directors, December 2000. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute Respiratory failure. Am J Respir Crit Care Med 2001;163:283-291. https://doi.org/10.1164/ajrccm.163.1.ats1000
  97. Esteban A, Anzueto A, Alia I, et al. How is mechanical ventilation employed in the intensive care unit? an international utilization review. Am J Respir Crit Care Med 2000;161:1450-1458. https://doi.org/10.1164/ajrccm.161.5.9902018
  98. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212. https://doi.org/10.1183/09031936.00114307
  99. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008;63:599-605. https://doi.org/10.1136/thx.2007.088112
  100. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009;180:3-10. https://doi.org/10.1164/rccm.200901-0047OC
  101. Raad D, Gaddam S, Schunemann HJ, et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Chest 2011;139:764-774. https://doi.org/10.1378/chest.10-0991
  102. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: a study of the general population. COPD 2010;7:5-10. https://doi.org/10.3109/15412550903499506
  103. Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD-Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008;102:1243-1247. https://doi.org/10.1016/j.rmed.2008.04.010
  104. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD003566.
  105. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-1894. https://doi.org/10.1093/eurheartj/ehi291
  106. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009;11:684-690. https://doi.org/10.1093/eurjhf/hfp066
  107. Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008;264:361-369. https://doi.org/10.1111/j.1365-2796.2008.01975.x
  108. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010;12:685-691. https://doi.org/10.1093/eurjhf/hfq050
  109. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11: 292-298. https://doi.org/10.1093/eurjhf/hfp001

Cited by

  1. Chronic Obstructive Pulmonary Disease: Respiratory Review of 2013 vol.76, pp.2, 2013, https://doi.org/10.4046/trd.2014.76.2.53